VanEck Pharmaceutical ETF
PPH
52 hedge funds and large institutions have $113M invested in VanEck Pharmaceutical ETF in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
21% more capital invested
Capital invested by funds: $93M → $113M (+$19.6M)
12.79% more ownership
Funds ownership: 33.43% → 46.22% (+13%)
4% more funds holding
Funds holding: 50 → 52 (+2)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
75% less call options, than puts
Call options by funds: $408K | Put options by funds: $1.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$23.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$3.8M |
| 3 |
SG Americas Securities
New York
|
+$2.77M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.52M |
| 5 |
CCT
Country Club Trust
Kansas City,
Missouri
|
+$937K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.79M |
| 2 |
Morgan Stanley
New York
|
-$1.81M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$723K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$706K |
| 5 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$589K |
PPH Hedge Fund Activity: Q1 2018 in Review
52 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2018, worth a combined $113M — up 21% from $93M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PPH positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 13 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $23.9M. The largest seller was UBS Group, cutting an estimated $4.79M.
- 52 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2018, up from 50 in Q4 2017.
- Funds reported $113M of VanEck Pharmaceutical ETF stock for Q1 2018, up 21% quarter-over-quarter.
- 5 funds opened new VanEck Pharmaceutical ETF positions in Q1 2018 and 3 closed out, a net change of +2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2018 was Goldman Sachs, an estimated $23.9M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2018 was UBS Group, an estimated $4.79M sold.
Based on aggregated 13F filings for Q1 2018.